Work

SIM2l attenuates resistance to hypoxia and tumor growth by transcriptional suppression of HIF1A in uterine cervical squamous cell carcinoma(本文)

Year: 2017
Type: dissertation
Abstract: Despite chemoradiotherapy being one of the most important modalities in advanced cervical cancer, there is a lack of both usable biomarkers to predict treatment outcome and of knowledge about the mechanism of refractoriness to the therapy.Here we identified a transcriptional factor Singleminded homolog 2 (SIM2) as an independent predictive biomarker for uterine cervical squamous cell carcinoma (CvSCC).The retrospective study showed that high expression level of SIM2 was correlated to good survival in CvSCC patients.SIM2 knockdown in CvSCC cell lines showed resistance to hypoxia with increased expression of HIF1A and its target genes.Loss of SIM2 also caused growth promotion, resistance to ROS, and radiation in 3D culture.Furthermore, SIM2 knockdown suppressed tumor growth with increased HIF-1α expression and angiogenesis in vivo.On the other hand, SIM2 long isoform (SIM2l)-overexpressed cells had contrary results, indicating the long isoform plays a key role for maintenance of these phenotypes.These data indicated that SIM2l has a potential to be precision medicine for CvSCC patients and that anti-angiogenesis therapy might be usable for SIM2l Low poor survivors.Among females, cervical cancer is one of the four most common malignancies, accounting for 528,000 new cases in 2012 and the fourth most common cause of cancer deaths worldwide, with an estimated 266,000 deaths in 2012 which are account for 7.5% of gynecological cancers 1 .A salient aspect of cervical cancer is chronic infection by various types of human papillomavirus (HPVs) which trigger carcinogenesis via integration of E6 and E7 oncogenes into the genome of host keratinocytes 2,3 .While cytology and vaccination-based cervical screening programs contribute to the amelioration of both incidence and mortality, the uptake of HPV vaccine has been poor, with 1-4% coverage of women worldwide and fewer in less-developed countries 4 .Indeed, death in less-developed region makes up more than 90% of the total 1 .Moreover, currently-used bivalent vaccines only target to HPV types 16 and 18, accounting for 70% of total cases, whereas 30% of patients who are infected by other types of HPVs result in incomplete protection from cervical cancer 5,6 .Prognoses of cases with early stages are reported to be relatively favorable (5-year survival rate of stage ΙA, ΙB, and ΙIA is 100%, 70-85%, and 70-85%, respectively), whereas those of advanced stages are still poor (5-year survival rate of stage ΙII and stage ΙV is 30-50% and 5-15%, respectively) 7 .Cervical squamous cell carcinomas (CvSCCs) account for approximately 75-80% of all cervical cancers and their primary management is well-established by each clinical stage.Surgery or radiotherapy alone is recommended for patients with early stages, and radiotherapy with/without cisplatin-based concurrent chemotherapy for patients with advanced stages 8,9 .However, the rates of distant and local relapse during 5 years after chemoradiotherapy are 14% and 19%, respectively 10 .Thus, a new modality to discover chemoradio-sensitive
Language: English
Subfield: Cancer Research
Open Access status: green
OpenAlex ID: W7134572812
Cites: 43
Cited by:
Related to: 10